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Mouse Models of Psoriasis
Johann E. Gudjonsson1, Andrew Johnston2, Melissa Dyson3, Helgi Valdimarsson2 and James T. Elder1,4,5
Psoriasis is a T-cell-mediated chronic inflammatory skin
disease believed to be of autoimmune nature that can
be triggered or worsened by streptococcal throat
infections. In addition to conventional chronic inflam-
matory changes, psoriasis is characterized by complex
and striking alterations in epidermal growth and
differentiation. Psoriasis is generally not observed in
animals other than man, and this lack of a suitable
animal model has greatly hindered research into the
pathogenesis of psoriasis. Multiple transgenic, knock-
out, and reconstituted models of psoriasis have
been developed over the past two decades. Despite
their limitations, these models have demonstrated that
keratinocyte hyperplasia, vascular hyperplasia, and cell-
mediated immunity in the skin are closely interrelated.
Xenograft models, in which involved and uninvolved
psoriatic skin are transplanted onto immunodeficient
mice, are the only models that come close to incorpor-
ating the complete genetic, immunologic, and pheno-
typic changes of the disease. They have shown
conclusively that psoriasis is a T-cell-mediated disease,
and have been used to elucidate novel pathogenic
pathways. In this review, we describe various animal
models, detail the immunologic and intracellular path-
ways that mediate these phenotypes and assess the
utility of these models to better understand this disease.
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INTRODUCTION
With two reported exceptions, a rhesus monkey (Lowe et al.,
1981) and a cynomolgus monkey (Zanolli et al., 1989),
psoriasis has not been observed in animals other than
humans. This lack of a suitable animal model has greatly
hindered research into the pathogenesis of psoriasis. How-
ever, over the past two decades, numerous mouse models
have been identified or created by genetic engineering that
mirror several aspects of psoriasis. Before these mouse
models are discussed in detail, it is important to realize the
profound differences that exist between mouse and human
skin (Figure 1). Aside from the obvious size difference
between mice and humans, the epithelium in fur-covered
mouse skin is disproportionately composed of densely
distributed hair follicles, whereas epithelium in human skin
is to a much greater extent interfollicular. This difference is
important as human epidermis shows differential expression
of proteins in the outer root sheath of the follicles compared
with the interfollicular areas (Schon et al., 1995). Mouse skin
does not share this feature, nor do the short inter-follicular
regions contain any rete ridges. Mouse epidermis generally
comprises of only 2–3 keratinocyte layers and is only
one quarter the thickness of human epidermis, and has a
faster epidermal turnover (Berking et al., 2002). Furthermore,
non-epithelial cutaneous tissue compartments also show
profound cross-species differences. Human dermis is sub-
stantially thicker than mouse dermis and contains fewer hair
follicles, and wounding is markedly different as mouse skin
regenerates effectively without significant scarring (Khavari,
2006). Finally, mice have an entire cutaneous muscle layer,
the panniculus carnosus that is only present in a rudimentary
form in humans as the platysma and other small muscles of
the face and neck.
Likewise, the immune system in mice differs from that of
humans in several ways. For example, mice have several
different subtypes of dendritic cells, including the
CD8þ dendritic cells and other inflammatory cells, such as
the dendritic epidermal T cells and NK1.1þ T cells that
are not found in humans (Godfrey et al., 2000; Ardavin,
2003; Jameson et al., 2004). Another factor is that humans
are outbred, whereas many of the mouse models discussed
are on inbred or congenic backgrounds. Importantly,
these models are usually based on manipulation of a single
gene, whereas psoriasis, in contrast, is thought to result
from interaction of multiple susceptibility loci (Bowcock
and Cookson, 2004). Furthermore, rodents can be, and
usually are, raised under controlled conditions, whereas
humans are not.
For an animal model to be useful as a tool for the study of
psoriasis, it should reflect many of the key histological
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features of the disease. Histologically, psoriasis is character-
ized by uniform elongation of rete ridges with thinning of the
suprapapillary epidermis. The tips of the rete ridges are often
clubbed or fused with adjacent ridges with edematous dermal
papillae containing dilated, tortuous capillaries, but despite
the edema, spongiosis (build up of fluid between keratino-
cytes) is mild or absent. Parakeratosis (retention of nuclei in
the stratum corneum) is another characteristic together with
thinning or absence of the granular layer. Parakeratosis may
be confluent or may alternate with orthokeratosis (nuclei
absent), and is inversely correlated with presence of the
granular layer (Cox and Watson, 1972). Collections of
neutrophils in the parakeratotic stratum corneum (Munro’s
microabscesses) are very common, and may occur, albeit less
frequently, in the spinous layer, where they may form
spongiform pustules of Kogoj (Gillum and Golitz, 2004).
The altered pattern of epidermal differentiation seen in
psoriasis has been termed regenerative maturation, because
it bears striking similarities to wound healing (Mansbridge
et al., 1984). Several molecular components of this response
(i.e., induction of the ‘‘hyperproliferative’’ keratins 6, 16, and
17, and altered expression of the epidermal differentiation
markers loricrin, involucrin, and filaggrin) are excellent
markers for therapeutic response in psoriasis (Vallat et al.,
1994). Furthermore, any useful model of this disease should
also reproduce the immunologic features of psoriasis, and
therefore respond to the same treatments that have been
shown to be effective in psoriasis.
In this review, we describe the various mouse models that
have been developed and reported to show features
reminiscent of psoriasis, we detail the immunologic and
intracellular pathways that mediate these phenotypes, and
assess the utility of these models to further our understanding
of this enigmatic disease.
Spontaneous mouse models
A number of spontaneous mouse mutations that give rise to
psoriasiform phenotypes have been described (Sundberg and
King, 1996; Raychaudhuri et al., 2001). These were the first
mice to hold the promise that an animal model of psoriasis
was obtainable.
The flaky skin (Ttc7fsn/Ttc7fsn) mouse displays a progres-
sive papulosquamous skin disorder. The hair shafts of these
mice have pits, striations, and outward growing protrusions.
Nails are bent at a 901 angle and have surface irregularities
with accumulation of scale at the nail base. The skin exhibits
intraepidermal invasion by neutrophils, increased epidermal
growth factor (EGF) receptor levels, and interestingly, a
positive Koebner reaction after tape-stripping, which resolves
after 6 weeks of treatment with oral, but not topical,
cyclosporine A (CsA), topical EGF, or UVB exposure
(Sundberg et al., 1994). Flaky skin mouse keratinocytes have
mitochondrial aberrations, and homozygotes also suffer
anemia and forestomach hyperplasia.
The spontaneous chronic proliferative dermatitis mutation
(cpdm/cpdm) is characterized by redness, alopecia, scaling,
and severe pruritus (HogenEsch et al., 1993). Histologically,
epithelial hyperproliferation is accompanied by infiltration of
eosinophils, macrophages, and mast cells, but only very few
T cells. Lesions similar to those in the skin occur in the
esophagus and forestomach (HogenEsch et al., 1993). The
phenotype could be reversed to some extent with cortico-
steroid treatment, but CsA was wholly ineffective. Topical
calcipotriene decreased cell proliferation, but had no effect
on epidermal thickness (Gijbels et al., 2000).
Homozygous asebia (Scd1ab/Scd1ab) mutant mice (Gates
and Karasek, 1965) are small, hunched, and have hypoplastic
sebaceous glands resulting from a defect in the stearoyl
coenzyme A desaturase-1 (Scd1) gene (Zheng et al., 1999).
Adult homozygotes develop scaly skin with generalized
alopecia. Histologically, the epidermis is thickened with
enlarged intercellular spaces and excessively long hair
follicles extending at a sharp angle into the deep subcutis.
The mutant mice have a thickened dermis characterized by
increased vascularity, increased cellularity, and prominent
fibroblasts. The dermal cellular infiltrate is rich in mast cells
and macrophages, but lacks T cells and neutrophils (Brown
and Hardy, 1988, 1989).
These spontaneous mutants often displayed some histolo-
gical features of psoriasis such as acanthosis, infiltration of
mast cells and macrophages, and increased vasculature
(Sundberg et al., 1990). However, the general absence of
T cells in the infiltrates (Wilkinson and Karasek, 1966;
Figure 1. Histological comparison of normal human (a, d), mouse skin (b, e)
and human-mouse xenograft (c, f). The figure shows a 0.4-mm-thick human
skin xenograft 42 days after transplantation into a NOD/LtSz-Prkdcscid/
Prkdcscid recipient, and serves to illustrate some of the differences in the
anatomy of human versus mouse skin described in the text. Note that no
human follicles are visible in the xenograft shown, which was derived from a
keratome biopsy of buttocks skin. Mouse epidermis generally comprises only
three cell layers and is o25 mm in thickness, whereas human epidermis
commonly constitutes 6–10 cell layers and is 450mm thick. It is also
noteworthy that the short inter-follicular regions in mouse skin do not contain
any rete ridges. Human dermis is substantially thicker than mouse dermis and
contains fewer hair follicles. Finally, mice contain an entire cutaneous muscle
layer, the panniculus carnosus.
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Sundberg et al., 1994) and lack of efficacy of anti-psoriasis
drugs (CsA, calcipotriene, and etretinate) (Gijbels et al., 2000)
suggest that these mice do not recapitulate all the pathologic
features of psoriasis.
Genetically engineered mouse models of psoriasis
Over the past two decades, various transgenic and gene
knockout mouse models have been created that demonstrate
some of the pathologic features observed in psoriasis. In most
of these models, either increased expression or knockout of
specific genes is directed to the basal layer of the epidermis
using promoters for the keratin genes KRT5 or KRT14, or to
the suprabasal layer using KRT1, KRT10, or involucrin (IVL)
promoter sequences. The similarity of these models to actual
psoriasis is compared in Figure 2. Further details of the
transgenes and targeted mutations for the models described
here can be found in Tables S1 and S2, respectively.
Targeted manipulation of the Stat3 pathway
Signal transducers and activators of transcription (STATs)
constitute a family of latent cytoplasmic proteins involved in
transmitting extracellular signals to the nucleus (Levy and
Darnell, 2002). One member, Stat3 (Figure 3a), has a critical
role in various biological activities, including cell prolifera-
tion, survival, and cell migration (Leonard and O’Shea,
1998; Hirano et al., 2000; Turkson and Jove, 2000; Levy
and Darnell, 2002). Persistent activation of Stat3 has been
implicated in carcinogenesis of squamous cell carcinoma of
the head and neck (Song and Grandis, 2000). In the skin,
Stat3 has an essential role in wound healing (Sano et al.,
1999, 2001) and is activated in psoriasis (Sano et al., 2005a).
It has also been shown to be a key regulator of keratinocyte
proliferation and survival following ultraviolet light B
irradiation (Sano et al., 2005b). Recently, a transgenic
mouse was developed, in which a constitutively active Stat3
mutation was expressed in basal keratinocytes using a bovine
KRT5 promoter: Tg(KRT5-Stat3*A661C*N663C)1Jdg (Table
S1) (Sano et al., 2005a). These mice developed skin lesions
resembling psoriasis either spontaneously or in response to
wounding by tape-stripping. The skin lesions showed
keratinocyte hyperplasia (acanthosis) with loss of the granular
layer and parakeratosis. Dilated blood vessels were
prominent, and a leukocytic infiltrate of lymphocytes and
neutrophils was observed. Most of the lymphocyte infiltrate
consisted of CD4þ T cells in the upper dermis and epidermis,
whereas the few CD8þ T cells that were seen were localized
predominantly within the epidermis. No phenotype was seen
when skin of these mice was transplanted onto immunodefi-
cient mice, but when activated T cells from the Stat3 mutant
mice were injected intradermally underneath the graft, the
psoriatic phenotype of the graft was generated. Thus, the
development of skin lesions in this model is dependent on
T-cell activation.
In another transgenic mouse model in which expression of
IL-20 was targeted to the basal layer using a KRT14 promoter,
Tg(KRT14-Il20)1Yac, aberrant keratinocyte differentiation
was seen (Blumberg et al., 2001). IL-20 and its receptors
are overexpressed in psoriatic skin (Blumberg et al., 2001),
and IL-20 is a potent activator of Stat3 (Blumberg et al., 2001)
(Figure 3a). In this model, abnormal keratinocyte differentia-
tion with expression of the regenerative maturation marker
K6 was seen. These mice also had thickened hyperkeratotic
epidermis and compact stratum corneum (Blumberg et al.,
2001). The stimulatory effect of IL-20 on the proliferation of
cultured keratinocytes was enhanced by IL-1b, EGF, and
tumor necrosis factor (TNF)-a (Blumberg et al., 2001). In a
similar model, in which IL-6 was expressed in the basal
layer under the control of a KRT14 promoter, Tg(Il6)1Efu,
minimal skin findings were seen apart from thickened
stratum corneum (Turksen et al., 1992). IL-6 is also a known
activator of Stat3 (Heinrich et al., 1998) and can also
activate the extracellular regulated kinase-mitogen activated
protein kinase pathway (Hirano et al., 2000). IL-6 has been
reported to be highly expressed in psoriatic epidermis
(Grossman et al., 1989), although other studies have not
been able to confirm this (Gearing et al., 1990; Elder et al.,
1992). These contradictory findings may be explained by a
report that IL-6 expression is greatest at the margins of
psoriatic plaques (Ohta et al., 1991). Interestingly, IL-6 has
also been shown to stimulate proliferation of cultured
keratinocytes (Grossman et al., 1989; Elder et al., 1992)
and, therefore, has a plausible role in the pathogenesis.
However, unlike the Stat3 mutant mouse discussed above, no
inflammatory infiltrates were observed in either the Tg(I-
l6)1Efu (Turksen et al., 1992) or the Tg(KRT14-Il20)1Yac
(Blumberg et al., 2001) transgenic mice.
Leptin is another potent inducer of Stat3 in keratinocytes
(Goren et al., 2003; Figure 3a). Leptin is a major adipocyte-
derived cytokine that is involved in the regulation of food
intake and energy expenditure. Leptin-deficient B6.V-Lepob/J
mice have severely delayed wound healing that can be
reversed by systemic or topical delivery of leptin (Frank et al.,
2000). In skin, the leptin receptor is exclusively expressed in
keratinocytes of the basal layer of the epidermis and the
hyperproliferative epithelium at the wound edge (Frank et al.,
2000). In a transgenic model that targeted overexpression of
leptin to basal keratinocytes, Tg(KRT5-Lep)1Flar, no obser-
vable effects on skin differentiation or proliferation were seen
(Rico et al., 2005), but wound healing impairment was
observed, probably secondary to leptin resistance. The role
of the leptin–leptin receptor system in psoriasis has not yet
been determined.
The features seen in these transgenic animals indicate that
signaling through the Stat3 pathway can result in some of the
features typically seen in psoriasis, including hyperprolifera-
tion of keratinocytes and altered differentiation. It is
noteworthy that in the Stat3 mutant mouse above, the
phenotype was dependent on immunocyte infiltration, but
no such infiltrate was seen in the Tg(Il6)1Efu, Tg(KRT14-
Il20)1Yac, or Tg(KRT5-Lep)1Flar transgenic models. This is
somewhat surprising, given that these three cytokines are
known to activate Stat3 in vitro. Given that the latter models
are dependent on ligand–receptor interaction, excess ligand
can lead to resistance to its effect and therefore a minimal or
even reverse phenotype as was observed in the leptin model.
It is also possible that, in addition to Stat3, the ligand–receptor
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Figure 2. Summary of various mouse models and their resemblance to human psoriasis –modified and expanded from Xia et al. (2003). The first row indicates
the characteristic changes seen in human psoriasis (Y, yes; N; no). Other models are compared with the human standard and are blocked in green if they
match human psoriasis or in red if they do not match. Question marks and the yellow blocks indicate that the feature in question was not examined. It is
noteworthy that several models have most of the listed features of psoriasis, although several of the features seen in the mice, like elongation of rete ridges, are
not as marked as in the human disease and are often difficult to evaluate given the increased density of hair follicles in mice. Given these similarities, it is
remarkable that only the xenograft models have so far been successfully used to investigate novel therapeutic agents. Further details of the models based on
**appear in Table S1 (transgenics) and 2b (targeted mutations). Xg: xenograft, Alg: MHC-mismatched allograft, and Sp: spontaneous mouse models.
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Figure 3. Some of the biochemical pathways manipulated in transgenic mouse models of psoriasis: STAT3, AP-1 and the NF-jB pathways. (a) Extracellular
components that activate STAT pathways include granulocyte colony stimulating factor (G-CSF) (Kamezaki et al., 2005), leptin (Goren et al., 2003), IL-6
(Sriuranpong et al., 2003), and IL-20 (Blumberg et al., 2001). Stat3 is activated through phosphorylation, followed by dimerization and nuclear translocation
(Levy and Darnell, 2002). (b) The Jun proteins (Jun, JunB, and JunD), together with the Fos proteins (Fos, FosB, Fra1, and Fra2) and some members of the ATF and
CREB protein families are the principal components of the AP-1 transcription factor family (Jochum et al., 2001). Jun plays an essential role in cell proliferation
by influencing a number of cell cycle regulators such as p53 and cyclin D1, whereas JunB negatively regulates cell growth by activating the p16INK4a inhibitor
and decreasing cyclin D1 expression (Weitzman, 2001). The balance of Jun proteins, with their opposing effects, has been proposed to determine whether
cells progress through the cell cycle or die (Weitzman, 2001). Both Jun and JunB knockout mice have an embryonic lethal phenotype (Szabowski et al., 2000).
(c) A multitude of extracellular signals are transduced to the nucleus via NF-kB and, crucially, these are controlled by the IkB kinase (IKK) complex. IKK is
activated by phosphorylation of its IKKa and IKKb subunits. IKK is then able to phosphorylate IkB, leading to its dissociation, ubiquitination, and destruction by
the proteasome. Once liberated, the active NF-kB dimer (p50 and Rel-A(p65)) enters the nucleus and induces gene transcription. IKKa may also form
homodimers, which are activated by NF-kB-inducing kinase (NIK) and lead to gene transcription by NF-kB2 (p52-Rel-B).
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interactions simultaneously activate other intracellular
pathways that serve to blunt leukocytic infiltration.
The AP-1 transcription factor family
Activator protein-1 (AP-1; Figure 3b) is a family of transcrip-
tion factors known to play an important role in keratinocyte
differentiation (Mehic et al., 2005), and their DNA-binding
activity has been reported to be decreased in psoriatic skin
(Johansen et al., 2004). In a recent paper (Zenz et al., 2005),
two members of the AP-1 family, JunB and Jun (c-Jun),
were knocked out in the epidermis of postnatal mice (Tg(Krt1-
5-cre/ERT)1Ipc with Junbtm3Wag or Juntm4Wag, or both,
Table S2). Single knockout mice had no observable changes,
but Junb Jun double knockouts developed psoriasis-like
features associated with severe arthritis. Lesional skin showed
infiltration of neutrophils and lymphocytes with upregulation
of several cytokines and chemokines typical for psoriasis.
However, IL-12 and IL-18 were absent, and IFN-g was only
slightly upregulated and in a delayed manner. The same
knockouts were established on immunodeficient mouse
backgrounds, including TNF receptor 1 knockout and
recombinase activating gene-2 (Rag2) knockout, which do
not have any functional T cells. This resulted in decreased
joint inflammation but minimal changes in the skin inflam-
mation, thus demonstrating that the inflammation in this
model was independent of T-cell function. The authors,
therefore, suggested that T cells might not be essential for
triggering psoriasis in humans. Given the considerable
evidence for a key role of T cells in the pathogenesis of
psoriasis (Gudjonsson et al., 2004), the relevance of this
model to psoriasis has been questioned (Gudjonsson and
Elder, 2005; Haider et al., 2006). Furthermore, other
studies have reported unchanged or even increased
levels of Jun and JunB in psoriasis (Basset-Seguin et al.,
1991; Johansen et al., 2004; Kulski et al., 2005; Haider et al.,
2006). The marked phenotype seen in this animal model,
which in many ways resembles the regenerative maturation
phenotype seen in psoriasis, raises the possibility that one
of the many genetic components that predispose to psoriasis
may involve a component of the AP-1 transcription
family. The role of AP-1 may extend beyond the keratinocyte
itself to involve intercellular communication between the
epidermis, mesenchyme, and the inflammatory infiltrate
(Schuh et al., 1990; Greenhalgh et al., 1993; Szabowski
et al., 2000).
Manipulation of the NF-jB pathway
IkB kinase (IKK) is a negative regulator of the NF-kB signal
transduction pathway and consists of the two catalytic
subunits (IKKa and IKKb) and a regulatory subunit (IKKg/
NEMO (NF-kappaB essential modulator)) (Figure 3c). The
IKKa and IKKb units phosphorylate IkB, targeting it for
degradation and thus inducing activation of NF-kB (reviewed
in Hayden and Ghosh, 2004). Mice with an epidermis-
specific deletion of IKKb (Tg(KRT14-cre)1Cgn with
Ikbkbtm1Mpa; Table S2) develop a severe inflammatory skin
disease, which is dependent on the dermal expression of
TNF-a (Pasparakis et al., 2002) and accumulation and
activation of dermal macrophages (Stratis et al., 2006).
Although the epidermis of these mice showed altered
differentiation and thickening, it had several characteristics,
including keratinocyte apoptosis, T-cell-independent inflam-
mation, and early death, which made it incompatible
with psoriasis (Figure 2). On the other hand, IKKa-deficient
mice (Chuktm1Ver; Table S2) showed abnormalities in
epidermal morphogenesis without inflammation, thus also
not resembling psoriasis (Li et al., 1999). There are indica-
tions that the DNA-binding activity of NF-kB is regulated
in a specific manner in psoriasis skin depending on the
specific DNA-binding sites investigated, not accompanied
by any change in the expression of the IKK proteins (Johansen
et al., 2005).
TGF-b and related mouse models
Transforming growth factor (TGF)-b1, b2, and b3 are
members of a large family of highly conserved yet pleiotropic
cytokines (Figure 4a). One or more of the TGF-b family
receptors and ligands are expressed in almost every tissue in
the body, and TGF-b1 has pivotal roles in T-cell development
and homeostasis (Gorelik and Flavell, 2002), and growth of
epithelial and endothelial cells (Miyazono et al., 2001).
Expression of TGF-b1 or its receptors or both has been found
to be increased (Kane et al., 1989), unaffected (Elder et al.,
1989), or decreased in psoriatic skin (Doi et al., 2003).
Several transgenic mouse models have been engineered that
target a constitutively active form of TGF-b1 (containing
C223S and C225S mutations) to the epidermis (Table S1).
When constitutive expression of active TGF-b1 was
targeted to suprabasal keratinocytes using the Tg(Tgfb1)1Der
transgene, the mice died within 24 h of birth due to inhibi-
tion of normal skin development (Sellheyer et al., 1993).
Similarly, in an inducible TGF-b1 system, Tg(tk-TGF-B1)
c1849DerTg(Lor-Gal4/PGR/VP16)c4486Der, sustained su-
prabasal expression of the TGF-b1 transgene exerted a
growth-inhibitory effect on the epidermis (Wang et al.,
1999). However, other transgenic animals, for example,
Tg(KRT10-TGF-B1*C223S*C225S)1Rosa (Cui et al., 1995)
and Tg(KRT6-Tgfb1)4Rosa (Fowlis et al., 1996), have shown
increased epidermal proliferation without hyperplasia when
expression was directed to the suprabasal layer. In another
conditional TGF-b1 system, using Tg(tetO-TGF-B1*C223S*
C225S)1Glk Tg(KRT5-rtTA)1Glk or Tg(KRT5-tTA)1Glk bi-
transgenic mice, active TGF-b1 expression was directed to
the basal layer under the control of the (reverse) tetracycline
transactivator. In this case, induction of TGF-b1 during
gestation caused embryonic death, whereas induction in
adult mice lead to keratinocyte proliferation, dermal fibrosis,
inflammation, and loss of hair growth (Liu et al., 2001). This
was associated with upregulation of Smad7 (Liu et al., 2001),
an inhibitor of TGF-b1 signaling (Miyazono et al., 2001),
suggesting that the hyperproliferative phenotype might have
resulted in part from the development of a sustained negative
feedback loop. Expression of the latent form of TGF-b1 in
the basal epidermal layer using Tg(KRT5-TGF-B1)F2020Xjw
transgenic mice resulted in a striking psoriasis-like phenotype
(Li et al., 2004). These animals exhibited a thickened stratum
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corneum with parakeratosis and a hyperplastic epidermis.
Scattered mononuclear cells were seen in the epidermis and
subcorneal microabscesses containing mixed mononuclear
cells and neutrophils, and prominent neovascularization.
Langerhans cells were sparse in the transgenic epidermis, a
feature also observed in human psoriasis (Gordon et al.,
2005). Integrin aEb7 expression was seen on epidermal T cells
in addition to upregulation of cytokines and chemokines,
characteristic of psoriasis; IL-1a, including macrophage
inflammatory protein-1b (MIP-1b, CCL4), TNF-a, IFN-g, and
vascular endothelial growth factor (VEGF). Interestingly
Smad7 expression was moderately upregulated, as was the
keratinocyte growth factor amphiregulin (Li et al., 2004).
Bone morphogenetic protein-6, another member of the
TGF-b superfamily, has also been overexpressed in the
suprabasal epidermis under the control of the KRT10
promoter (Tg(KRT10BMP6)VI632Mbl) (Blessing et al., 1996;
Wach et al., 2001). Depending on the pattern of transgene
expression, the effects on proliferation and differentiation
were opposite. Strong and uniform expression of the bone
morphogenetic protein-6 transgene resulted in severe repres-
sion of cell proliferation with marginal effects on differentia-
tion, whereas weaker and patchy expression of the transgene
evoked strong hyperproliferation and parakeratosis. Severe
perturbation of the usual pattern of differentiation was
seen along with an inflammatory infiltrate in both dermis
and epidermis. Interestingly, these mice were resistant to
induced chemically skin carcinogenesis, most likely owing to
a downregulation of AP-1 constituents (Wach et al., 2001).
Such resistance to neoplastic transformation is a feature of
psoriasis, but the underlying mechanism is incompletely
understood (Nickoloff, 2004).
These studies demonstrate that perturbations in TGF-b
signaling can lead to abnormal differentiation and hyperpro-
liferation of keratinocytes. On the basis of these models, it is
apparent that constitutive overexpression of active TGF-b and
related factors lead to a different phenotype than those
engendered by low, intermittent, and or focal expression.
Similarly, the metabolic form of TGF-b is also important.
Interestingly, the psoriatic-like phenotype is more likely to
be associated with the expression of Smad7, an inhibitory
element of the TGF-b signaling pathway, rather than
activation of Smad2 and Smad3 (Figure 4a). This is consistent
Figure 4. Some of the biochemical pathways manipulated in transgenic
mouse models of psoriasis: TGF-b signaling and integrin pathways.
(a) TGF-b1 is secreted in a latent form, which after release of a
latency-associated peptide, signals via a heterodimeric receptor complex
consisting of one of seven type I receptors (TGF-bRI, or activin receptor-like
kinases, ALK) and a type II receptor (TGF-bRII). On binding a ligand, the type
II receptor recruits and phosphorylates the type I receptors, which
activate the downstream signaling mediators Smads 2, 3, and 4
(Kretzschmar and Massague, 1998). Interestingly, the known target
genes for TGF-b1 are members of the AP-1 family (Wach et al., 2001)
(Jonk et al., 1998; Ueyama et al., 1998; Choi et al., 1999; Hollnagel et al.,
1999). (b) Each integrin is a heterodimer of an a and a b subunit, which
determine the ligand-binding specificity (Hynes, 1992, 2002). b1 integrins
are expressed throughout the proliferative compartment of the epidermis
(Bata-Csorgo et al., 1993). In healthy intact epidermis, b1 is restricted
to the basal layer; however, suprabasal integrin expression (spinous
and granular layer, GL) is a feature of hyperproliferative epidermis
as found in wound closure (Grose et al., 2002), psoriasis (Pellegrini
et al., 1992), and neoplastic keratinocyte disorders (Bagutti et al.,
1998).
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with human psoriatic lesions, in which TGF-b2 and TGF-b3
and their receptors are downregulated and Smad2 mRNA
levels are decreased (Doi et al., 2003). Another possibility is
that the hyperproliferation is secondary to an effect on the
dermis. Fibroblasts in transgenic skin, in addition to
inflammatory cells, have been shown to contribute to
epidermal hyperproliferation through production of growth
factors, such as keratinocyte growth factor and insulin-like
growth factor-1 (Miura et al., 2000). These results highlight
the complexity of TGF-b signaling in skin.
Transgenic expression of integrins, collagenase, and IL-1a
The integrins form a large family of cell-surface receptors
that mediate cell–cell and cell–extracellular matrix adhesion.
A number of integrin knockout mice with a range of
epidermal phenotypes have been engineered (Hynes, 1992,
2002; Watt, 2002). Of particular interest are animals with
altered expression of the b1 integrins as these are typically
restricted to the basal layer, and are involved in the control
of keratinocyte proliferation and inhibition of terminal
keratinocyte differentiation (Figure 4b; Levy et al., 2000). In
a transgenic mouse model where b1 expression was directed
to the suprabasal layer of the epidermis (Table S1; Carroll
et al., 1995), the animals began to show flaking of the
epidermis with inflammation after 6 weeks of age. Interest-
ingly, some of the animals went through cycles of exacerba-
tions and spontaneous remissions. Pathologically, the
lesional skin showed several features of psoriasis, including
parakeratosis and an inflammatory infiltrate characterized by
neutrophilic pustules, CD8þ T cells in the epidermis and
CD4þ T cells in the dermis (Carroll et al., 1995). Increased
activation of mitogen-activated protein kinase in basal and
suprabasal keratinocytes was also seen (Haase et al., 2001).
MEK1 (MAP2K1) is an upstream kinase of the extracellular
regulated kinase-mitogen-activated protein kinase. When
a constitutively active, MEK1 mutant was expressed in
the suprabasal epidermis (Tg(IVL-MEK1*S217E*S221E)
3062Fmw), a phenotype very similar to the b1 integrin
transgenics was seen (Hobbs et al., 2004). In both models,
increased production of IL-1a was seen. Interestingly, when
the MEK1 model was crossed with another strain over-
expressing the IL-1 receptor, exacerbated hyperproliferation
and inflammation was seen (Hobbs et al., 2004). Similarly,
overexpression of IL-1a in the basal layer of the epidermis
(Tg(Il1a)1.1Tsk; Table S1) led to hyperproliferation of
keratinocytes, with infiltration of the macrophage/monocyte
lineage (Groves et al., 1995). Given the phenotype of the IL-
1a transgenic mouse, it was not surprising that mice lacking
the IL-1 receptor antagonist (Il1rntm1Nick) had psoriasis-like
features, including hyperproliferative epidermis with inflam-
matory infiltrate (Shepherd et al., 2004). This phenotype was
dependent on the background mouse strain, with BALB/c
being the only strain showing both cutaneous and joint
inflammation (Shepherd et al., 2004). In contrast to this, IL-1
activity has been shown to be reduced in psoriatic skin
lesions, attributed to reduced IL-1a levels and the presence of
IL-1 inhibitors (Cooper et al., 1990). The IL-1/IL-1 receptor
system contains many checks and balances, and further study
is needed to understand how transgenic dysregulation of this
system leads to psoriasis-like features.
When human tissue collagenase was overexpressed in
mouse epidermis, psoriasis-like features were unexpectedly
seen (D’Armiento et al., 1995). Tissue collagenase is a matrix
metalloproteinase (MMP1) expressed in most tissues that
undergo remodeling and is expressed physiologically
by keratinocytes involved in wound healing (Donoff et al.,
1971). When this enzyme was targeted to the suprabasal
layer (Tg(HP-MMP1)50Cha; D’Armiento et al., 1995), the
mice (Haptoglobin-collagenase) had dry and scaly skin, with
histology showing keratinocyte hyperproliferation and, inter-
estingly, these animals had augmented sensitivity to epider-
mal carcinogenesis. Collagenase expression also caused
disruption of the epidermal architecture in the transgenic
mice, although there are no known fibrillar collagens within
the epidermis. The underlying mechanism of the phenotype
mediated by the expression of this enzyme would, therefore,
be expected to be either indirect by inducing expression of
other degradative proteinases, or by the direct action of
collagenase on other substrates in the epidermis. Disruption
of intercellular contact by degradation of collagenase-
sensitive material between keratinocytes could be thought
of as a type of microtrauma and might have triggered wound-
healing processes leading to hyperproliferation of keratino-
cytes and regenerative maturation.
Manipulation of growth factors and related mechanisms
Various growth factors are upregulated in psoriatic lesions,
including the EGF-like growth factors amphiregulin
(Piepkorn, 1996), TGF-a (Elder et al., 1989) and heparin
binding epidermal-like growth factor (Stoll and Elder, 1998),
VEGF (Detmar et al., 1994), and nerve growth factor (Fantini
et al., 1995; Pincelli, 2000; Pincelli and Marconi, 2000).
Each of these growth factors is also overexpressed during
epidermal wound healing (James et al., 1991; Frank et al.,
1995; Stoll et al., 1997; Matsuda et al., 1998; Shirakata
et al., 2005). Several of these factors have been over-
expressed in transgenic mice with resulting psoriasis-like
phenotypes, suggesting that these factors play a role in the
formation and maintenance of psoriatic lesions. Amphiregu-
lin and heparin-binding epidermal-like growth factor are
heparin-binding members of the EGF family. Amphiregulin
has distinct biochemical (Cook et al., 1991) and biological
(Chung et al., 2005) properties from those of the non-heparin
binding factors TGF-a and EGF. Transgenic expression of
amphiregulin in the basal layer (Tg(KRT14-AREG)3Pwc,
Table S1) resulted in a severe inflammatory skin phenotype
characterized by prominent scaling, alopecia, papillomatous
epidermal growths, inflammatory infiltrate of neutrophils and
lymphocytes, and dilated blood vessels within the upper
dermis (Cook et al., 1997). Interestingly, some of these mice
also developed arthritis (Cook et al., 2004). Perhaps owing to
the presence of massive inflammation, these animals
had a markedly shortened lifespan and growth restriction.
In contrast to this, when TGF-a was overexpressed in basal
layer of the epidermis, Tg(Tgfa)1Efu (Vassar and Fuchs, 1991),
only mild focal thickening of the skin and stunted hair growth
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were observed. We were also unable to observe a hyperpro-
liferative or inflammatory phenotype in transgenic mice
engineered to overexpress heparin-binding epidermal-like
growth factor in the basal layer (Stefan Stoll and James T
Elder, unpublished data). Intraperitoneal injection of anti-
bodies directed against amphiregulin inhibited the
hyperplastic response in a xenograft model of psoriasis
(Bhagavathula et al., 2005), supporting the notion that this
growth factor is important in the psoriatic pathomechanism.
However, further studies are needed to determine whether
amphiregulin is truly unique among EGF-like growth factors
in its ability to elicit a psoriasiform phenotype.
In a mouse model in which VEGF was targeted to the basal
layer of the epidermis (Tg(KRT14-Vegfa)1Gdy; Table S1), the
mice developed a phenotype very similar to psoriasis
(Xia et al., 2003; Kunstfeld et al., 2004). Histologically, the
skin in these mice demonstrated hyperplastic and inflamed
dermal blood vessels, epidermal thickening with aberrant
keratinocyte differentiation, and characteristic inflammatory
infiltrates. This phenotype could be reversed by a VEGF
antagonist (Xia et al., 2003). VEGF is a potent mediator of
angiogenesis and its levels are elevated in psoriatic skin
(Detmar et al., 1994). Expression of the VEGF receptor
was originally thought to be restricted to endothelial cells,
but recent reports have demonstrated the presence of VEGF
receptors on human keratinocytes (Wilgus et al., 2005).
Interestingly, VEGF signals through Stat3 (Bartoli et al., 2003)
and induces proliferation of normal human keratinocytes
(Wilgus et al., 2005). Thus, some of the phenotype seen in
this model could be due to direct action of VEGF on
keratinocytes. Whether antipsoriatic therapies showed any
efficacy was not reported (Xia et al., 2003; Kunstfeld et al.,
2004).
Another interesting mouse model, based on conditional
expression of the tyrosine kinase receptor Tie2 (Tg(Tek-
tTA)1Dmt Tg(TetOS-Tek)1Dmt), was recently published
(Voskas et al., 2005, Table S1). This receptor binds angio-
poietins and has been shown to control angiogenic remodel-
ing (Sato et al., 1995). Expression of Tie2 and the
angiopoietins have been shown to be upregulated in human
psoriasis (Kuroda et al., 2001). With the activation of the
transgene, the mice developed extensive erythema, with
loosely adherent silver-white scaling. Histologically, the
epidermis was thickened with elongation of the rete
pegs, compact hyperkeratosis, and focal parakeratosis.
Furthermore, an inflammatory infiltrate and neutrophilic
microabscesses were seen with increased number of
blood capillaries. Interestingly, complete resolution was
seen when the mice were treated with CsA (Voskas
et al., 2005). Although CsA can have an effect on cells
other than T cells, this generally requires much higher
doses than required for treatment of psoriasis (Behnam et al.,
2005). Given the lack of information regarding the CsA
dosing in this paper, it is unclear whether this improvement
was because of the well-known immunosuppressive effects
of CsA, or because of some other secondary effects of this
drug, which are only seen at very high doses (Hernandez
et al., 2001).
To date, there are no published studies of mice over-
expressing nerve growth factor in the epidermis. However,
treatment of a mouse xenograft model of psoriasis with a
pharmacologic inhibitor of nerve growth factor signaling led
to clinical improvement (Raychaudhuri et al., 2004).
T-cell-based mouse models of psoriasis
Several models have been established which aberrant T-cell
function results in a phenotype similar to psoriasis. When
severe combined immunodeficient mice (SCID mice) on an
ICR background were reconstituted with minor histocompat-
ibility-mismatched naive (CD45RBhi) CD4þ T cells, 100% of
the animals developed skin lesions 4–8 weeks after the
transfer (Schon et al., 1997). The skin lesions had many
features similar to psoriasis, including thickening and
hyperkeratosis of the epidermal layer, parakeratosis, infiltra-
tion of immunocytes, and proliferation of blood vessels.
A number of cytokines characteristic of psoriasis were
upregulated, including IFN-g, TNF-a, IL-1a, VEGF, and IL-6.
Interestingly, reconstitution with CD4þ memory/effector
(CD45RBlo) T cells did not lead to any phenotype, and
coinjection of these cells with naive (CD45RBhi) CD4þ
resulted in a less severe phenotype. Furthermore, these
mice responded to CsA and ultraviolet light B treatment. No
evidence of apoptosis, characteristic of graft-versus-host
disease, was seen. It was shown that the skin infiltrating
CD4þ T cells were predominantly memory/effector cells
(CD45RBlo) (Hong et al., 1999) and that coadministration of
IL-12 greatly enhanced the disease phenotype, whereas
antibodies against the common p40 subunit of IL-12 and IL-
23 prevented disease development. Surprisingly, transfer
of naive CD45RBhiCD4þ T cells from IFN-g-deficient
(C.129S7(B6)-Ifngtm1Ts/J) mice led to delayed onset but
otherwise identical disease. In contrast to psoriasis, no
CD8þ T cells were seen in the epidermis (Hong et al.,
1999). A similar inflammatory skin phenotype, which was
also shown to be T-cell-dependent (Breban et al., 1996), was
seen in rats transgenically expressing high levels of HLA-B27
and human b2-microglobulin (Tg(HLA-B*2705, B2M)33-
3Trg; Table S1). However, these animals also developed
multisystem inflammatory disease characterized by arthritis
and colitis (Hammer et al., 1990). Although overexpression of
HLA-B27 in mice was not associated with skin disease, these
mice can develop arthritis and nail changes if the mouse
b2-microglobulin gene is either knocked out (B2 mtm1Unc)
or replaced with the human homologue (Khare et al., 1995,
1996). Whether this difference is related to host genetic
background or different levels of transgene expression
remains to be clarified.
A T-cell-dependent inflammatory skin disease resembling
psoriasis is seen in mice with a hypomorphic mutation of the
gene encoding CD18 (Itgb2tm1Bay) backcrossed to mice of PL/
J background (PL.129S7-Itgb2tm1Bay; Bullard et al., 1996;
Figure 2). b2 integrins are leukocyte adhesion molecules
exclusively expressed on hematopoietic cells and responsible
for cell–cell contacts in a variety of inflammatory interactions
(Kess et al., 2003). The common b-chain (CD18) associates
with four different a subunits, forming distinct functional
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heterodimers termed lymphocyte function-associated antigen
(LFA)-1 (CD11a/CD18), Mac-1 (CD11b/CD18), gp150,95
(CD11c/CD18), and CD11d/CD18 (Kess et al., 2003). These
interact with over 20 ligands, of which the most prominent
belong to the ICAM (intercellular adhesion molecule) family
(Carlos and Harlan, 1994; Springer, 1994). Interestingly, only
the PL/J mice with the hypomorphic CD18 mutation
(Itgb2tm1Bay) backcrossed from 129S7 mice developed skin
disease, but not mice expressing the wild-type or null
(Itgb2tm2Bay) alleles. Moreover, the disease did not develop
in ICAM-1-deficient (Icam1tm1Bay) mice (Sligh et al., 1993).
Likewise, no phenotype was observed when the mutation
was backcrossed to different mouse strains (C57BL6/J or
129S7), indicating the existence of important modifier genes
(Kess et al., 2003). The inflammatory lesions were character-
ized by influx of immunocytes and expression of Th1
cytokines such as IFN-g. However, in contrast to psoriasis
(Uyemura et al., 1993), the Th2 cytokine, IL-10, was also
slightly increased. Interestingly, treatment with a monoclonal
antibody against CD4þ T cells resulted in complete
remission, whereas antibodies against CD8þ T cells had no
effect (Kess et al., 2003). Given the effect of the anti-CD4
antibodies, it is likely that this phenotype is due to either
dysregulation or generation of autoreactive lymphocytes, as
LFA-1 is one of the factors involved in the regulation of
apoptosis during negative selection of autoreactive thymo-
cytes (Quddus et al., 1994). Furthermore, b2 integrins are also
crucial for the adjustment of antigen-dependent activation
threshold of T cells (Bachmann et al., 1997). This model was
recently demonstrated to be dependent on TNF-a production
by activated macrophages (Wang et al., 2006).
Another model that should be mentioned in this context is
the cutaneous inflammatory disorder observed in integrin aE
(CD103)-deficient mice (Itgaetm1Cmp; Table S2; Schon et al.,
2000). The aEb7 integrin is normally expressed by T cells in
mucosal and epidermal sites and is thought to mediate
intraepithelial retention of T cells (Sigmundsdottir et al.,
2004). Interestingly, the expression of this integrin is a marker
for a subset of highly potent, functionally distinct regulatory
T cells specialized for crosstalk within epithelial environ-
ments (Lehmann et al., 2002). The phenotype of these mice
would indicate that aEb7 integrin is directly involved in the
function or generation of these regulatory cells as loss of its
expression results in such a severe inflammatory phenotype.
The skin lesions in this model (Figure 2) were characterized
not only by hyperproliferation of keratinocytes, hyperker-
atosis, and increased vascularity, but also by ulcerative skin
lesions, which are not a feature of psoriasis.
Mice lacking the transcription factor interferon regulatory
factor (IRF)-2 (Irf2tm1Mak; Table S2) developed an inflamma-
tory skin disease, characterized by erythema, hair loss and
increased proliferation of keratinocytes. Several abnormal-
ities not characteristic of psoriasis were also observed,
including a disorganized muscle layer and associated
prominent fibrosis (Hida et al., 2000). IRF-2 is thought to
function as a negative regulator of gene expression by
antagonizing IFN-a/b signaling. This is important as IFN-a
has been implicated in the pathogenesis in psoriasis
(Nestle et al., 2005). Interestingly, this disease appeared to
be predominantly mediated by CD8þ T cells as selective
depletion of these cell delayed the onset of the skin disease
(Hida et al., 2000).
More recently, a model based on the expression
of an autoimmunity-prone ab TCR was developed
(Tg(TcraMM14.4,TcrbMM14.4)500Ach; Table S1; Logunova
et al., 2005). Mice that have had their major histocompat-
ibility complex class II peptide diversity reduced to a single
complex may be prone to autoimmunity, and in this
case developed significant numbers of ‘‘autoreactive’’ T
cells, resulting in multisystem inflammation. Logunova and
co-workers cloned one of the autoimmunity-prone TCRs
(MM14.4) and transgenically expressed it with the result that
mice developed an inflammatory skin disease resembling
psoriasis (Figure 2). Interestingly, although this TCR was
cloned from a CD4þ T cell, the psoriasiform dermatitis was
mediated by effector CD8þ T cells (Logunova et al., 2005).
The only other T-cell-dependent model, the constitutively
active Stat3 model, was described earlier. As increasing
number of data indicate that psoriasis is a T-cell-mediated
disease (Gudjonsson et al., 2004), with antigen-specific
responses against an epidermal antigen (Johnston et al.,
2004), these T-cell-dependent animal models directly
demonstrate and support the concept that T cells can induce
psoriasiform skin lesions.
Models based on targeted cytokine expression
Several interesting transgenic models have been developed
that overexpress some of the cytokines that characterize
psoriasis. TNF-a is a cytokine that is overexpressed in
psoriasis (Ettehadi et al., 1994) and targeted therapy against
this cytokine is a highly effective treatment in a significant
majority of patients (Leonardi et al., 2003), indicating that it
has a central role in the disease process. Interestingly,
overexpression of this cytokine in the epidermis of transgenic
animals, Tg(Krt14-TNF)1Efu, led to retarded hair growth,
inhibition of adipose production and signs of fibrosis, and
immune infiltration in the dermis with subsequent necrosis
and cachexia (Cheng et al., 1992).
Another cytokine thought to be central in the pathogenesis
of psoriasis is IFN-g (Barker et al., 1991). It is a prototypical
Th1 cytokine and is a potent mediator of T-cell-mediated
immune responses. Intradermal injection of IFN-g into normal
skin induced keratinocyte proliferation (Barker et al., 1993),
and psoriasis can be induced at the injection site of IFN-g in
uninvolved psoriatic skin (Fierlbeck et al., 1990). Further-
more, T-cell clones isolated from psoriasis skin lesions have
been shown to induce keratinocyte proliferation in an IFN-g-
dependent manner (Prinz et al., 1994). Transgenic expression
of IFN-g in the suprabasal epidermal layer of mice (Tg(IVL-
Ifng)C1205Fmw; Table S1) resulted in striking hypopigmenta-
tion of the hair due to the reduced abundance of melano-
cytes. Severely affected mice had reddened skin, growth
retardation, hair loss, and flaky skin lesions. Keratinocyte
proliferation was increased and there was epidermal
thickening with spongiosis and parakeratosis and infiltration
of inflammatory cells with a decrease in Langerhans cells,
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a process having more resemblance to contact dermatitis
or other eczematous processes than psoriasis (Carroll
et al., 1997).
Likewise, mice that were constitutively made to express
the common p40 subunit of IL-12 and IL-23 in basal
keratinocytes (Tg(KRT14-Il12b)1Tsk; Table S1) developed an
eczematous skin disease that was characterized by hyperker-
atosis, focal epidermal spongiosis, and inflammatory infiltrate
(Kopp et al., 2001). Subcutaneous injections of IL-12 resulted
in a skin phenotype comparable to that of the p40 transgenic
mice. IL-12 is a heterodimer of the p35 and p40 subunits and
is a known inducer of IFN-g (Trinchieri, 1995). IL-23 is a
heterodimer of p40 and p19, but is functionally divergent
from IL-12 and is thought to be a key player in chronic
inflammation by inducing development of a separate T-cell
subset characterized by IL-17 production (Langrish et al.,
2004). In a subsequent study (Kopp et al., 2003), it was
shown that this phenotype was due to epidermal production
of IL-23, but not IL-12, and demonstrated that the phenotype
could be reproduced by subcutaneous IL-23 injections.
Interestingly, these mice also had enhanced cutaneous
immunity as demonstrated by accelerated graft rejection
(Kopp et al., 2003).
Xenografts as models of psoriasis
Xenotransplantation offers an alternative approach to the
transgenic expression of inflammatory mediators for the
development of an animal model of psoriasis. These models,
in which uninvolved non-lesional psoriatic skin or plaque
psoriasis skin is transplanted onto severely immunodeficient
mice, currently come closest to incorporating the complete
genetic, phenotypic, and immunopathogenic processes of
psoriasis (Wrone-Smith and Nickoloff, 1996; Boyman et al.,
2004). Several mouse strains have been used for this purpose
(Table S3).
Nude mice
Initial investigations focused on athymic nude mice (Krueger
et al., 1981). Using this approach, it was shown that psoriatic
features of transplanted affected skin could be maintained
for more than 2 months without further manipulation
(Fraki et al., 1982). These mice possess a vestigial thymus,
which is incapable of producing mature T cells. This results
in impaired T-cell functions, as demonstrated by an
absence of a delayed type hypersensitivity reaction, inability
to reject skin allografts, and decreased antibody responses
to some T-cell-dependent antigens. However, their
response to T-independent antigens is normal and they have
no defects in natural killer (NK) cell function (Meyerrose
et al., 2003).
SCID mice
SCID mice lack both humoral and cellular immunity due to a
mutation in the DNA-dependent protein kinase (protein
kinase, DNA-activated, catalytic polypeptide, Prkdcscid) gene
that is required for successful T-cell receptor and immuno-
globulin gene rearrangements and thus is essential for T- and
B-cell development. The SCID mutation also confers extreme
radiosensitivity due to inability to repair double-stranded
DNA breaks (Takahashi et al., 2002). One well-utilized
SCID mouse, CB.17-Prkdcscid/Prkdcscid, retains high NK cell
numbers and function, whereas the SCID mutation on other
backgrounds can be more amenable to engraftment, for
example, non-obese diabetic/LtSz-Prkdcscid/Prkdcscid mice
that have additional defects in NK and macrophage function.
Although the SCID mice accept transplants of solid tissues,
single-cell suspensions are rapidly recognized and lysed by
mouse NK cells (Meyerrose et al., 2003). Therefore, T-cell
engraftment in this model is very poor. Although skin grafts
are well accepted and maintained in these mice, the grafts
gradually decrease in size (Takizawa et al., 1995) and
become hyperplastic (Nickoloff et al., 1995), a feature that
was less marked in more severely immunodeficient strains
(Takizawa et al., 1997). Despite this, SCID mice have been
widely used for psoriasis research and are capable of
maintaining the disease process for weeks to months in
transplanted lesional skin. This model has also been used for
evaluating efficacy of novel biologic agents in preclinical
studies (Villadsen et al., 2003). Nickoloff and co-workers
showed that by injecting large numbers of autologous
superantigen-stimulated blood-derived immunocytes under
the transplanted non-lesional skin (PN) from a psoriatic
patient, it was possible to induce conversion into psoriasis
plaque skin (PP) in 9 out of 10 patients studied (Wrone-Smith
and Nickoloff, 1996). Importantly, control skin from normal
individuals showed no changes. This model demonstrated
conclusively that psoriasis is a T-cell-mediated disease.
However, its utility has been limited by its logistical
complexities.
AGR129 mice
A novel xenotransplantation model was recently described
(Boyman et al., 2004), in which psoriatic skin lesions develop
spontaneously when PN skin is engrafted onto AGR129 mice.
AGR129 are triple knockout mice deficient in type I and type
II IFN receptors and lacking the recombinase activating
gene-2 gene. These mice lack T- and B-cells and have
immature NK cells with severely impaired cytotoxic activity
in vitro and in vivo (Boyman et al., 2004). Upon engraftment,
resident human T cells in uninvolved psoriatic skin were
shown to undergo local proliferation and activation. This is
crucial for development of the psoriatic phenotype, as
treatment of the grafts with anti-CD3 antibody prevented
the conversion into lesional skin (Boyman et al., 2004). The
psoriatic phenotype developed in 28 out of 31 (90%)
mice grafted. Phenotypic conversion started at week 4 and
was fully developed by 6–8 weeks after engraftment. The
development of the lesion was associated with expansion
of T cells within the graft, especially the epidermal CD8
T cells (Boyman et al., 2004). This model has already been
used to elucidate novel pathogenic mechanisms in psoriasis
(Nestle et al., 2005).
Although the type I interferon defect in these mice may
play a role in this spontaneous phenotype (Nestle et al.,
2005), several lines of evidence suggest that lack of host NK
cell function is likely to be the critical factor. Mouse NK cells
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may hinder the development and proliferation of the
T cells residing in the graft (Meyerrose et al., 2003), which
is also highlighted by the fact that an absence of NK
cell function can result in a 12- to 20-fold better engraftment
by hematologic and immunologic cells, especially T cells
(Shultz et al., 2003). Moreover, in the presence of even
suboptimal host NK activity, human T cells survive and
undergo expansion after hematological xenotransplantation
only if extremely high numbers of T cells are transplanted
(Gorin et al., 2002). In skin transplantation models, this can
only be achieved by transplantation of lesional skin contain-
ing many activated T cells (Villadsen et al., 2003) or by
injecting large numbers of pre-activated T cells underneath
the nonlesional graft (Wrone-Smith and Nickoloff, 1996). It
is enticing to speculate that residual NK function in the
early immunodeficient mouse models was the reason for graft
shrinkage and why inflammatory processes diminish after
several weeks of engraftment (Sugai et al., 1998). Consistent
with this hypothesis, it was recently demonstrated that
killing of donor antigen-presenting cells in an allograft skin
transplant model was mediated by host NK cells (Yu et al.,
2006). No studies have been carried out to address
specifically this point in skin xenotransplantation.
In the AGR129 mouse model, non-psoriasis control (NN)
skin did not transform to a psoriasis-like phenotype, which is
consistent with the assertion that T cells residing in the PN
skin are essential for the development of the lesion. This is
supported by the effectiveness of anti-CD3 antibodies in
preventing the PN to PP transformation in the AGR129 model
(Boyman et al., 2004). Given that PN skin has increased
numbers of dermal and epidermal T cells compared with NN
skin (Baker et al., 1988), it is possible that NN skin contains
too few T cells to propagate this transformation. However, it
is likely that the difference between NN skin and PN skin is
more than just sheer numbers of T cells. In the human SCID
model, NN skin could not be converted to PN skin even
when large numbers of activated autologous T cells are
injected into the graft (Wrone-Smith and Nickoloff, 1996).
Some tissue response was seen when NN skin was loaded
with activated T cells, just as erythema and an increase in
keratinocyte proliferation is seen following injection of
IFN-g into non-psoriatic skin (Fierlbeck et al., 1990). The
activated T cells are likely to release cytokines that promote
local inflammation in NN skin, but we would speculate that
in the absence of their cognate antigen, these cells do not
trigger the development of a full-fledged psoriatic lesion.
However, in psoriasis patients from whom increased circulat-
ing T-cell responses to potential epidermal autoepitopes have
been demonstrated (Johnston et al., 2004), the injected
autologous T cells may recognize their cognate autoantigen
in the graft and proliferate causing development of the
psoriatic lesion.
Although the xenotransplant models are currently the best
mouse models of psoriasis that we have, they have several
limitations. They are technically difficult as they require large
keratome sheets or multiple punch biopsies from patients,
and the grafting needs to be performed quickly to minimize
graft ischemia.
CONCLUSION
There is a frequent sentiment among scientists that an animal
model must exactly mimic the human disease that is being
studied. However, this goal is only rarely attained. Failure of
an animal model to meet the criteria for a specific human
disease is ascribed to four major sources (Sundberg, 1994):
the animal system is incompletely or inaccurately described;
the human disease is incorrectly or incompletely described;
there are species-specific differences in biological processes
that are important for the disease process; there are
differences between inbred and outbred animals. In the
Introduction, we discussed several differences in the cuta-
neous anatomy and the immune systems of mice and
humans. Thus, even if the precise primary molecular defects
in human psoriasis were known and could be transferred to
mice, it is certainly possible that the resulting disease in mice
would not look exactly like psoriasis in humans. Moreover, it
is widely accepted that psoriasis is a polygenic disease, and
most of the models developed by genetic engineering so far
are based on single gene manipulations. Indeed, the fact that
several mouse models do recapitulate most, if not all, aspects
of the psoriatic phenotype (Figure 2) is very encouraging. The
existence of these models indicates that there are well-
conserved cellular interactions between the epidermis, dermis,
vasculature, and inflammatory and immune cells that can be
perturbed to produce a state of ‘‘psoriasiform’’ inflammation
via derangement of specific molecules and pathways.
Although there is a great need for good animal models of
psoriasis for manipulative or treatment studies, researchers
should be careful not to choose a suboptimal or incorrect
model. As can be seen in Figure 2, many of the mouse models
only have incomplete information regarding their pheno-
types, demonstrating that there is a definite need for a
standardized scoring system that would enable researchers to
compare different models and their compatibility to psoriasis.
Such a scoring system has been suggested recently (Nickoloff,
2006).
One important caveat is that some of the mutations
discussed may present as different phenotypes when expressed
in mice of different background strains; for example, IL-1ranull
(Il1rntm1Nick; Shepherd et al., 2004), CD18hypo (Itgb2tm1Bay;
Kess et al., 2003), and SCID (Prkdcscid; Meyerrose et al., 2003).
Thus, careful selection, definition, and monitoring of strain
background is of paramount importance.
Although the transgenic and knockout strains developed
so far can and have been proven to be extremely useful for
development and testing of therapeutics targeted against the
specific pathway being disrupted, none of them have yet
been used for large-scale testing or development of novel
targeted treatments in psoriasis. To date, only the xenograft
models have been used in that regard (Villadsen et al., 2003).
It should be emphasized that the xenograft models come
closest to incorporating the complete genetic, phenotypic,
and immunopathogenic processes of psoriasis, and currently
have the greatest potential to increase our understanding of
the pathomechanisms involved in psoriasis compared with
other available mouse models. However, it is probable that
with increased knowledge of the structure and function of the
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genetic components involved in psoriasis susceptibility, we
will be able to develop more tractable yet faithful animal
models of this challenging disease.
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NOTE ADDED IN PROOF
Since submission of this manuscript a new model of psoriasiform hyperplasia
has been described. In this model, psoriasiform hyperplasia (Djalilian et al.,
2006) was seen in mice lacking the transcription factor Krupple-like factor 4
(Klf4) and this was associated with upregulation of the gap junction protein
connexin 26 (Cx26). Interestingly, ectopic expression of Cx26 reproduced the
same phenotype.
SUPPLEMENTARY MATERIAL
Table S1. Details of the transgenes used in the models described in the text.
Table S2. Details of targeted mutations outlined in the text.
Table S3. Selected immunodeficient mouse strains suitable for xenotrans-
plantation.
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